Lantern Pharma (NASDAQ: LTRN) reported second-quarter 2026 operational and financial results, showcasing significant advancements in its AI-driven oncology pipeline and the establishment of Open Medicine AI (“OMAI”) as a separate company. These developments underscore the company's commitment to leveraging artificial intelligence to accelerate cancer therapy development and create new revenue streams.
The most notable clinical progress came from the Phase 2 HARMONIC trial evaluating LP-300 in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Emerging data revealed that the progression-free survival benefit deepened with longer treatment duration in patients with EGFR exon 21 L858R mutations. Additionally, the U.S. Food and Drug Administration (FDA) reviewed key protocol amendments without objection, allowing the trial to proceed as planned. These findings are crucial because they suggest LP-300 may offer a targeted benefit for a specific patient subgroup, potentially improving outcomes in a challenging cancer type.
In the European Union, the European Medicines Agency (EMA) cleared an investigator-initiated Phase 1b/2 trial of LP-184 (zirdafulven) in biomarker-selected advanced bladder cancer. This approval expands the clinical development of LP-184 beyond its current focus on pancreatic and other solid tumors. Moreover, the U.S. Patent and Trademark Office issued a Notice of Allowance for a three-gene patient-selection signature for LP-184, which could enable more precise patient identification in future trials, enhancing the drug's efficacy and safety profile.
Strategically, Lantern made a bold move in August by establishing OMAI as a wholly owned subsidiary and entering into board-approved commercial licensing agreements for its multi-agentic AI co-scientist platform, previously launched as withZeta.ai. This platform is now commercially available as a subscription-based research tool for the global biomedical and drug development community. By spinning out OMAI, Lantern aims to unlock the value of its AI capabilities, potentially attracting new partnerships and revenue streams. This is a pivotal step as the company seeks to capitalize on the growing interest in AI-driven drug discovery.
Financially, Lantern reported a second-quarter loss from operations of approximately $3.5 million, a 25% improvement from the $4.7 million loss in the same period last year. Research and development expenses declined by 42% to approximately $1.8 million, reflecting disciplined spending. However, the net loss widened to approximately $7.1 million, or $0.57 per share, compared to $4.3 million, or $0.40 per share, a year earlier. The increase was largely due to approximately $3.6 million in warrant-related expenses. As of June 30, 2026, the company held cash, cash equivalents, and marketable securities totaling approximately $7.4 million, which may raise questions about its runway, but the reduced operating loss and potential revenue from withZeta.ai could provide some cushion.
The establishment of OMAI as a separate entity is particularly significant. It allows Lantern to focus on its core oncology pipeline while giving the AI platform the flexibility to serve a broader market. The withZeta.ai platform, now commercialized, represents a new revenue stream that could diversify Lantern's income beyond traditional drug development milestones. This move aligns with a broader industry trend of pharma companies monetizing their AI assets.
Lantern's progress in the clinic and its strategic pivot toward AI commercialization are important for investors and patients alike. The deepening PFS benefit in the HARMONIC trial could position LP-300 as a viable option for a subset of lung cancer patients, while the advancement of LP-184 into bladder cancer opens new indications. The company's ability to secure intellectual property and regulatory clearances underscores the potential of its AI-driven approach.
As Lantern continues to evolve, the success of OMAI and the clinical outcomes of its pipeline will be critical. The company's focus on precision oncology, guided by its proprietary RADR platform, aims to match the right drug to the right patient, potentially improving efficacy and reducing side effects. With the AI platform now generating revenue, Lantern may be better positioned to fund its ongoing trials and expand its pipeline.
For more information, visit the company's newsroom at https://nnw.fm/LTRN.
